Previous 10 | Next 10 |
home / stock / drmaw / drmaw news
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announc...
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical ...
- Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 - - FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies o...
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies- - Dermata also submitted an end of phase 2 meeting package to the FDA - SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or...
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the closing of its previously announced p...
SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 sh...
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 - - Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 - - DMT410 partnering discussions ongoing - SAN DIEGO, CA / ACCESSWIRE / Febru...
- Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints - - DMT310 produced no serious adverse events related to treatment - - Dermata remains on track to request an End of Phase 2 meeting with the FDA for DMT310 for ...
- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 - SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("D...
Dermata completes a $5.0 million private placement financing in April 2022 DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022 SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"),...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics, Inc. (NASDAQ: DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuanc...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...